Prostate Cancer

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

"It was a really interesting paper to develop and write, because over the past decade, there's been such a paradigm shift in the treatment of prostate cancer," says Dr Louise Kostos.

"The primary end point was radiographic progression-free survival, which we reported in 2023, and we updated the radiographic progression-free survival data in 2025," says Neeraj Agarwal, MD, FASCO.

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.

"I think that 1 of the main reasons physicians weren't necessarily acting is that they weren't getting a full picture of how aggressive the disease was," says Alicia Morgans, MD, MPH.

“As we move through 2025, I think we're going to see more and more expansion of new ideas, new isotopes, and possibly improvement in PET imaging for the future,” says Jason M. Hafron, MD, CMO.

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

"Our findings highlight that completing 5 cycles or more of radium was associated with a 2- to 5-fold increase in overall survival," says Rana R. McKay, MD, FASCO.

"The most critical next step is to focus on enhancing both the scientific rigor of our clinical trials and the personalization of our treatment," says Channing J. Paller, MD.

"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT.

Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.

"I think the most important thing to improve our reporting of PSA doubling time is to remind clinicians why it's important to even calculate this number," says Alicia Morgans, MD, MPH.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.

"We found that actually, many, many physicians were not reporting PSA doubling time," says Alicia Morgans, MD, MPH.

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

The median number of re-injections was 6 (range, 1-12).

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

In both racial cohorts, median MFS was not reached in the darolutamide group.